Hemispherx BioPharma (HEB)

[NickPar]

CDC Joint Briefing with NIH & FDA on 2009 H1N1 Influenza
August 21, 2009, 12:00 p.m.

This telephone conference call was an update on the H1N1 flu and included adjuvant testing.

No company names were given about whose adjuvants but it appears that no stone is being left unturned as they prepare for worst case scenario.

The meeting was handled by Glen Nowak who introduced the following 3 people:
Mr. Jay Butler, Director of CDC's H1N1 Vaccine Task Force,
Dr. Jesse Goodman, Acting Chief Scientist and Deputy Commissioner at the Food and Drug Administration,
Dr. Anthony Fauci, the Director of the National Institute of Allergy and Infectious Diseases at the National Institutes for Health

Full Transcript: http://www.cdc.gov/media/transcripts/2009/t090821.htm

Of the six people asking questions, one of particular interest to HEB was asked by Helen Branswell of the Canadian press:

...And my second question relates to adjuvants. Given the yield problem and the fact that vaccine is going to becoming in slower than the U.S. had first anticipated, is the U.S. looking more strongly at the use of adjuvants?

Answered by Dr. Anthony Fauci: ...we are planning trials using adjuvants in what we call a mix and match, where we take the antigen from one company, Sinofia CFL and use the adjuvant from another company. Those studies are scheduled to start somewhere in mid to late September. The overall total number of individuals and trials will be approximately 4,500 to 4,600 individuals.

GLTA
HEB long